A Landmark Trial (without an FDA approval)
from OncoPharm Hosted by John Bossaer
An abbreviated edition of our Landmarks in #OncoPharm series returns to discuss weekly cisplatin + radiotherapy for locally advanced cervical cancer. As a bonus, we cover a new study establishing FOLFOX as the standard-of-care for 2nd line treatment of metastatic biliary cancer. All of this is discussed against the backdrop of the relative importance (or lack thereof?) of obtaining an approved indication.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 13 minutes long.
When was this OncoPharm episode published?
This episode was published on April 29, 2021.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.